SCHEMBL14626708

SCHEMBL14626708

CC(=O)Cc1ccc2nc(-c3ccccc3C)oc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.53
▸ MAPT P10636 5/20 0.49
▸ NPC1 O15118 3/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ CASP3 P42574 2/20 0.49
▸ SENP8 Q96LD8 2/20 0.49
▸ SENP7 Q9BQF6 2/20 0.49
▸ SENP6 Q9GZR1 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ PDCD1 Q15116 1/20 0.46
▸ CD274 Q9NZQ7 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ VSIR Q9H7M9 1/20 0.45
▸ IKBKB O14920 1/20 0.43
▸ KDR P35968 3/20 0.43
▸ ESR1 P03372 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14591807 0.87 TP53 (0.50) TP53MAPTNPC1RAB9AKDM4E
SCHEMBL14626722 0.86 KDR (0.54) TP53MAPTNPC1RAB9AKDM4E
SCHEMBL14627052 0.86 ATM (0.44) TP53MAPTNPC1RAB9AKDM4E
SCHEMBL14626711 0.83 CASP3 (0.61) MAPTNPC1RAB9AKDM4ECASP3
SCHEMBL14627049 0.78 ITGB1 (0.55) NPC1RAB9AKDM4EALDH1A1TSHR
SCHEMBL9197515 0.77 ESR1 (0.68) TP53MAPTNPC1RAB9AKDM4E
SCHEMBL22686244 0.77 HSD17B10 (0.64) TP53MAPTNPC1RAB9AKDM4E
SCHEMBL14626645 0.76 KDM4E (0.66) TP53MAPTNPC1RAB9AKDM4E
SCHEMBL28636530 0.74 RAB9A (0.78) TP53MAPTNPC1RAB9AKDM4E
SCHEMBL2434406 0.74 ESR1 (0.63) TP53MAPTNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 — — US disclosed
Send feedback